These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25769789)

  • 1. Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments.
    Vives J; Oliver-Vila I; Pla A
    Cytotherapy; 2015 Aug; 17(8):1009-14. PubMed ID: 25769789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variations in novel cellular therapy products manufacturing.
    Fontaine MJ; Selogie E; Stroncek D; McKenna D; Szczepiorkowski ZM; Takanashi M; Garritsen H; Girdlestone J; Reems JA;
    Cytotherapy; 2020 Jun; 22(6):337-342. PubMed ID: 32223996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concluding commentary on current trends to enhance the clinical safety of pediatric transfusion, focusing on prevention of untoward complications of HSC transplantation & newer strategies for improving the standards of safety/quality of stem cells expansion for cellular therapy.
    Sniecinski I; Seghatchian J
    Transfus Apher Sci; 2018 Jun; 57(3):378-383. PubMed ID: 29778713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The translation of cell-based therapies: clinical landscape and manufacturing challenges.
    Heathman TR; Nienow AW; McCall MJ; Coopman K; Kara B; Hewitt CJ
    Regen Med; 2015; 10(1):49-64. PubMed ID: 25562352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications.
    Wuchter P; Bieback K; Schrezenmeier H; Bornhäuser M; Müller LP; Bönig H; Wagner W; Meisel R; Pavel P; Tonn T; Lang P; Müller I; Renner M; Malcherek G; Saffrich R; Buss EC; Horn P; Rojewski M; Schmitt A; Ho AD; Sanzenbacher R; Schmitt M
    Cytotherapy; 2015 Feb; 17(2):128-39. PubMed ID: 24856898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stem cells for therapeutic purposes.
    Sensebé L; Bourin P
    Transplantation; 2009 May; 87(9 Suppl):S49-53. PubMed ID: 19424006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?
    Roura S; Gálvez-Montón C; Mirabel C; Vives J; Bayes-Genis A
    Stem Cell Res Ther; 2017 Oct; 8(1):238. PubMed ID: 29078809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First clinical case report of local microinjection of autologous fat and adipose-derived stromal vascular fraction for perianal fistula in Crohn's disease.
    Philandrianos C; Serrero M; Grimaud F; Magalon J; Visée C; Velier M; Francois P; Orsoni P; Magalon G; Grimaud JC; Desjeux A; Véran J; Sabatier F
    Stem Cell Res Ther; 2018 Jan; 9(1):4. PubMed ID: 29321063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations on chemistry, manufacturing, and control of stem cell products for Investigational New Drug application in China.
    Lu J; Wei W
    Biologicals; 2020 Nov; 68():3-8. PubMed ID: 33097376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell therapy for myocardial infarction: Special delivery.
    Heldman AW; Hare JM
    J Mol Cell Cardiol; 2008 Mar; 44(3):473-6. PubMed ID: 18234211
    [No Abstract]   [Full Text] [Related]  

  • 11. Old and new challenges in Parkinson's disease therapeutics.
    Pires AO; Teixeira FG; Mendes-Pinheiro B; Serra SC; Sousa N; Salgado AJ
    Prog Neurobiol; 2017 Sep; 156():69-89. PubMed ID: 28457671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic cell therapy manufacturing: process development technologies and facility design options.
    Abbasalizadeh S; Pakzad M; Cabral JMS; Baharvand H
    Expert Opin Biol Ther; 2017 Oct; 17(10):1201-1219. PubMed ID: 28699788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stem cell-based therapy for nonhealing wounds: today and tomorrow.
    Li M; Zhao Y; Hao H; Han W; Fu X
    Wound Repair Regen; 2015; 23(4):465-82. PubMed ID: 25877885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cells for myocardial infarction.
    McNiece I
    Cytotherapy; 2015 Mar; 17(3):243-4. PubMed ID: 25659639
    [No Abstract]   [Full Text] [Related]  

  • 15. Mesenchymal stem cell therapy in treatment of erectile dysfunction: Autologous or allogeneic cell sources?
    Kadihasanoglu M; Ozbek E
    Int J Urol; 2016 Apr; 23(4):348-9. PubMed ID: 26822742
    [No Abstract]   [Full Text] [Related]  

  • 16. Cell Therapy for Chronic Limb-Threatening Ischemia: Current Evidence and Future Directions.
    Teraa M; Gremmels H; Wijnand JGJ; Verhaar MC
    Stem Cells Transl Med; 2018 Dec; 7(12):842-846. PubMed ID: 30070050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotherapy using stromal cells: Current and advance multi-treatment approaches.
    Shende P; Gupta H; Gaud RS
    Biomed Pharmacother; 2018 Jan; 97():38-44. PubMed ID: 29080456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regenerative cell and tissue-based therapies for pulmonary arterial hypertension.
    Foster WS; Suen CM; Stewart DJ
    Can J Cardiol; 2014 Nov; 30(11):1350-60. PubMed ID: 25442435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal autologous stem cells.
    Falavigna A; da Costa JC
    World Neurosurg; 2015 Feb; 83(2):236-50. PubMed ID: 23402865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing mesenchymal stem cell-based therapeutics.
    Wagner J; Kean T; Young R; Dennis JE; Caplan AI
    Curr Opin Biotechnol; 2009 Oct; 20(5):531-6. PubMed ID: 19783424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.